BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
This Quarter Return
+8.86%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$604M
AUM Growth
+$604M
(+11%)
Cap. Flow
+$16.4M
Cap. Flow
% of AUM
2.72%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
3
Reduced
–
Closed
1
Top Buys
| 1 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
$12M |
| 2 |
IMDX
Insight Molecular Diagnostics Inc. Common Stock
IMDX
|
$4.08M |
| 3 |
Lineage Cell Therapeutics
LCTX
|
$454K |
Top Sells
| 1 |
AST.WS
Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017)
AST.WS
|
$164K |
Sector Composition
| 1 | Healthcare | 45.79% |
| 2 | Consumer Staples | 43.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Monster Beverage
MNST
$60.9B
| $265M | 43.9% | 4,797,408 | – | – |
|
2
STAAR Surgical
STAA
$1.36B
| $135M | 22.38% | 10,855,179 | – | – |
|
|
3
Lineage Cell Therapeutics
LCTX
$267M
| $77.5M | 12.83% | 27,279,254 +160,000 | +0.6% | +$454K |
|
4
iShares Russell 2000 ETF
IWM
$67B
| $62.2M | 10.31% | 420,000 | – | – |
|
|
IMDX
5
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $27.2M | 4.5% | 3,596,680 +540,000 | +18% | +$4.08M |
|
|
MNK
6
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $24.1M | 3.99% | 644,822 +322,411 | +100% | +$12M |
|
|
AST
7
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
| $12.6M | 2.08% | 3,699,848 | – | – |
|
|
AST.WS
8
DELISTED
Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017)
AST.WS
| – | – | -328,205 | Closed | -$164K |
|